Getagraph.com logo
S&P 500 Futures
(0.25%) 5 144.50 points
Dow Jones Futures
(0.27%) 38 544 points
Nasdaq Futures
(0.36%) 17 910 points
Oil
(-0.80%) $83.18
Gas
(1.30%) $1.948
Gold
(-0.12%) $2 344.30
Silver
(1.20%) $27.58
Platinum
(0.66%) $928.20
USD/EUR
(-0.28%) $0.932
USD/NOK
(-0.25%) $11.00
USD/GBP
(-0.42%) $0.797
USD/RUB
(0.85%) $92.66

Realaus laiko atnaujinimai Suven Life Sciences [SUVEN.NS]

Birža: NSE Sektorius: Healthcare Pramonė: Drug Manufacturers—Specialty & Generic
Atnaujinta29 bal. 2024 @ 08:32
25% discount on Stockinvest.us - Use code: Podcast

1.84% INR 113.50

Live Chart Being Loaded With Signals

Commentary (29 bal. 2024 @ 08:32):

Suven Life Sciences Limited, a clinical-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel therapeutics for the treatment of neurodegenerative disorders in India, the United States, Europe, and internationally...

Stats
Šios dienos apimtis 65 604.00
Vidutinė apimtis 254 289
Rinkos kapitalizacija 24.75B
EPS INR0 ( 2024-01-29 )
Kita pelno data ( INR0 ) 2024-05-06
Last Dividend INR1.382 ( 2019-02-14 )
Next Dividend INR0 ( N/A )
P/E -23.79
ATR14 INR0.198 (0.17%)

Tūris Koreliacija

Ilgas: 0.16 (neutral)
Trumpas: -0.71 (moderate negative)
Signal:(54.069) Neutral

Suven Life Sciences Koreliacija

10 Labiausiai teigiamai susiję koreliacijos
10 Labiausiai neigiamai susiję koreliacijos

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Suven Life Sciences Koreliacija - Valiuta/Žaliavos

The country flag 0.32
( neutral )
The country flag 0.24
( neutral )
The country flag 0.00
( neutral )
The country flag 0.16
( neutral )
The country flag -0.06
( neutral )
The country flag 0.11
( neutral )

Suven Life Sciences Finansinės ataskaitos

Annual 2022
Pajamos: INR135.39M
Bruto pelnas: INR129.74M (95.82 %)
EPS: INR-6.63
FY 2022
Pajamos: INR135.39M
Bruto pelnas: INR129.74M (95.82 %)
EPS: INR-6.63
FY 2022
Pajamos: INR118.44M
Bruto pelnas: INR118.44M (100.00 %)
EPS: INR-8.86
FY 2021
Pajamos: INR134.78M
Bruto pelnas: INR134.78M (100.00 %)
EPS: INR-5.67

Financial Reports:

No articles found.

Suven Life Sciences Dividends

(Q3/22) (Q4/22) (Q1/23) (Q2/23) (Q3/23) (Q4/23) (Q1/24) (Q2/24) (Q3/24) (Q4/24)
INR0
(N/A) 		INR0
(N/A) 		INR0
(N/A) 		INR0
(N/A) 		INR0
(N/A) 		INR0
(N/A) 		INR0
(N/A) 		INR0
(N/A) 		INR0
(N/A) 		INR0
(N/A)

Suven Life Sciences Dividend Information - No Dividend Player

Dividend Sustainability Score: 0 - low (50.00%) | Divividend Growth Potential Score: 1.881 - No dividend growth expected in the near future
Information
First Dividend INR0.230 2004-09-10
Last Dividend INR1.382 2019-02-14
Next Dividend INR0 N/A
Payout Date 2019-02-25
Next Payout Date N/A
# dividends 16 --
Total Paid Out INR8.02 --
Avg. Dividend % Per Year 0.00% --
Score 0.66 --
Div. Sustainability Score 0
Div.Growth Potential Score 1.881
Div. Directional Score 0 --
Next Divdend (Est)
 (2024-11-12)
INR0 Estimate 0.00 %
Dividend Stability
0.04 Very Bad
Dividend Score
0.66
Pay Frequency
Annually
Yearly Payout
Year Amount Yield
2004 INR0 0.00%
2005 INR0 0.00%
2006 INR0 0.00%
2007 INR0 0.00%
2008 INR0 0.00%
2009 INR0 0.00%
2010 INR0 0.00%
2011 INR0 0.00%
2012 INR0 0.00%
2013 INR0 0.00%
2014 INR0 0.00%
2015 INR0 0.00%
2016 INR0 0.00%
2017 INR0 0.00%
2018 INR1.382 0.73%
2019 INR1.382 0.60%
2020 INR0 0.00%
2021 INR0 0.00%
2022 INR0 0.00%
2023 INR0 0.00%
2024 INR0 0.00%

Dividend Commentary

The company does not currently pay dividends. Given its current dividend status and a low Dividend Growth Potential Score (DGPS), there's minimal likelihood of dividends being initiated soon. Considering all factors, the near-term dividend outlook for the company remains unpromising.

Top 10 dividend Companies for NSE

Symbol Title Last dividend Frequency Years Dividend Yearly Dividend Score
SILINV.NS Dividend Junior 2023-08-18 Annually 23 0.63%
MBAPL.NS Dividend Junior 2023-09-18 Annually 8 0.44%
GUJAPOLLO.NS Ex Dividend Junior 2023-09-22 Annually 18 0.48%
BAYERCROP.NS Dividend Junior 2023-08-03 Annually 15 1.25%
PREMIERPOL.NS Dividend Junior 2023-09-11 Sporadic 9 0.39%
KAMDHENU.NS Dividend Junior 2023-08-14 Sporadic 17 0.32%
EDELWEISS.NS Dividend Junior 2023-09-18 Annually 17 2.38%
ADSL.NS Dividend Junior 2023-08-10 Sporadic 16 0.91%
STERTOOLS.NS Dividend Junior 2023-09-11 Annually 19 0.38%
NAHARCAP.NS No Dividend Player 2023-09-08 Annually 17 0.70%

Dividend Sustainability Score (DSS)

RatioActual ValueWeightNormalized ValueScoreRange
netProfitMarginTTM-8.911.500-10.00-10.00[0 - 0.5]
returnOnAssetsTTM01.20000[0 - 0.3]
returnOnEquityTTM-0.2981.500-4.42-6.63[0.1 - 1]
payoutRatioTTM0-1.00000[0 - 1]
currentRatioTTM00.800-5.00-4.00[1 - 3]
quickRatioTTM00.800-4.71-3.76[0.8 - 2.5]
cashRatioTTM01.500-1.111-1.667[0.2 - 2]
debtRatioTTM0-1.50000[0 - 0.6]
interestCoverageTTM-652.211.000-10.00-10.00[3 - 30]
operatingCashFlowPerShareTTM0.6112.009.8010.00[0 - 30]
freeCashFlowPerShareTTM0.6112.009.6910.00[0 - 20]
debtEquityRatioTTM0-1.50000[0 - 2.5]
grossProfitMarginTTM-1.6861.000-10.00-10.00[0.2 - 0.8]
operatingProfitMarginTTM-9.991.000-10.00-10.00[0.1 - 0.6]
cashFlowToDebtRatioTTM01.000-1.111-1.111[0.2 - 2]
assetTurnoverTTM00.800-3.33-2.67[0.5 - 2]
Total Score-4.38

Dividend Growth Score (DGS)

RatioActual ValueWeightNormalized ValueScoreRange
peRatioTTM-22.891.000-2.410[1 - 100]
returnOnEquityTTM-0.2982.50-2.84-6.63[0.1 - 1.5]
freeCashFlowPerShareTTM0.6112.009.8010.00[0 - 30]
dividendYielPercentageTTM01.50000[0 - 0.4]
operatingCashFlowPerShareTTM0.6112.009.8010.00[0 - 30]
payoutRatioTTM01.50000[0 - 1]
pegRatioTTM0.3321.500-1.1210[0.5 - 2]
operatingCashFlowSalesRatioTTM1.1191.00010.000[0.1 - 0.5]
Total Score1.881

Suven Life Sciences

Suven Life Sciences Limited, a clinical-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel therapeutics for the treatment of neurodegenerative disorders in India, the United States, Europe, and internationally. The company engages in drug discovery and development of new chemical entities (NCEs) in central nervous system therapies. Its product candidates include SUVN-502 for the treatment of Alzheimer's disease and neuropsychiatric symptoms; SUVN-G3031, a potent and selective histamine H3 receptor inverse agonist for the treatment of sleep and cognitive disorders; and SUVN-911, a novel, potent, and selective a4ß2 nicotinic acetylcholine receptor antagonist for the treatment of depressive disorders. The company is also developing SUVN-D4010, a potent, selective, and orally bio-available and brain penetrant 5-HT4 receptor partial agonist for the treatment of cognitive disorders; SUVN-I6107 for the treatment of cognitive disorders and schizophrenia; SUVN-M8036 for the treatment of psychiatric disorders; and SUVN-D1044 for the treatment of gastrointestinal disorders. The company was formerly known as Suven Pharmaceuticals Pvt. Ltd. and changed its name to Suven Life Sciences Limited in 2003. The company was incorporated in 1989 and is headquartered in Hyderabad, India. Suven Life Sciences Limited is a subsidiary of Jasti Property and Equity Holdings Private Limited.

Apie Signalai gyvai

Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.

Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.